Gilead Sciences, Inc. has announced its financial results for the third quarter of 2026, showcasing a notable 13% increase in product sales compared to the same period last year. This performance is significant for the company, as it reflects the strength and growth of its core business segments, particularly in HIV and oncology.

On October 29, 2026, Gilead reported that total product sales reached $8.3 billion, driven primarily by higher sales of HIV products, as well as Trodelvy® and Livdelzi®. However, this growth was partially offset by lower sales of Veklury® and cell therapy products. The company's strong performance has led to an increase in its full-year revenue guidance by $1.6 billion since the start of 2026.

Gilead Sciences, Inc. is a Delaware corporation operating in the biological products sector, specifically under the SIC code 2836, which encompasses biological products excluding diagnostic substances. The company trades on the Nasdaq under the ticker symbol GILD.

According to the recent SEC filing (accession number 0000882095-26-000037), Gilead's Chairman and CEO, Daniel O’Day, stated, “Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade.” He highlighted the company's performance in the HIV segment, which grew by 18%, and noted that HIV prevention sales nearly doubled year-over-year.

In terms of earnings, Gilead reported diluted earnings per share (EPS) of $1.94 for the third quarter, down from $2.43 in the same period last year. This decline was attributed to net losses from equity securities, increased operating expenses, and higher income tax expenses. However, non-GAAP diluted EPS increased to $2.55, up from $2.47, driven by higher product sales and lower acquired in-process research and development expenses.

The filing indicates that Gilead's strong performance may have implications for its competitors in the biological products industry. As Gilead continues to grow its market share, other companies in the sector may need to adapt their strategies to remain competitive.

Looking ahead, Gilead's filing does not specify what actions will follow this report, but the company is likely to continue focusing on its growth strategies in HIV and oncology, as well as exploring new opportunities in inflammation and other therapeutic areas.